Skip to main content

Table 3 Statistical correlation of anti-NMDAR antibody with parameters obtained from clinical rating scales in the patient group of the study

From: N-Methyl-d-aspartate (NMDA) receptor antibody in relation to autism spectrum disorder (ASD): presence and association with symptom profile

Parameter NMDA Test of significance
Negative Positive
Mean ± SD Mean ± SD Value p-value Sig.
N (%) N (%)
ADOS level of Autism related symptoms Mild 4 (6.25%) 3 (13.04%) X2 = 3.786 0.151(C) NS
Moderate 29 (45.31%) 14 (60.87%)
High 31 (48.44%) 6 (26.09%)
Probability to diagnose ASD in GARS 87 (65–89) 35 (19–84) U = 414.5 0.002(M) S
Stereotyped behavior most affected Sensory 30 (46.88%) 12 (52.17%) X2= 4.621 0.099(C) NS
Verbal 27 (42.19%) 5 (21.74%)
Motor 7 (10.94%) 6 (26.09%)
Stereotyped behavior degree Low 32 (50%) 12 (52.17%)   < 0.001(F) S
Below average 32 (50%) 5 (21.74%)
Average 0 (0%) 6 (26.09%)
Vineland’s domain most affected Communication 21 (32.81%) 8 (34.78%)   0.474(F) NS
Daily life 0 (0%) 0 (0%)
Social 19 (29.69%) 7 (30.43%)
Motor 0 (0%) 1 (4.35%)
Communication + Social 24 (37.5%) 7 (30.43%)
Total calibrated score of Vinland Adaptive Behavior Scale 31 (26–31) 45 (39–51) U = 247.0 < 0.001(M) S
Age coefficient 0.16 (0.13–0.27) 0.28 (0.2–0.4) U = 365.5 < 0.001(M) S
  1. SD Standard deviation, N Number, S Significant, NS Not significant, (T)Student’s t-test of significance (t = Student’s t-test value). (C)Chi-square test of significance (X2 = chi-square test value). (F)Monte-Carlo Fisher’s exact test of significance. (M)Mann-Whitney test of significance (U = Mann-Whitney’s test value)